Targeting a specific protein to improve immunotherapy for brain tumors
Targeting SEC61 complex to overcome resistance to immunotherapy in GBM
This study is looking at a protein called SEC61G to see if it helps glioblastoma, a tough brain tumor, resist treatments, and if targeting this protein can make immunotherapy work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11047949 on NIH RePORTER |
What this research studies
This research investigates the role of the SEC61 complex in glioblastoma (GBM), a challenging brain tumor that often resists immunotherapy. By using advanced techniques like CRISPR-Cas9, the researchers aim to identify how the SEC61G protein contributes to this resistance. The study will explore whether targeting SEC61G can enhance the effectiveness of T cell-mediated therapies in treating GBM. Patients may benefit from a better understanding of how to overcome resistance to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to current immunotherapy treatments.
Not a fit: Patients with other types of brain tumors or those who have not been diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with glioblastoma by enhancing the effectiveness of immunotherapy.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this novel approach for glioblastoma.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Balyasnikova, Irina V — Northwestern University at Chicago
- Study coordinator: Balyasnikova, Irina V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.